Literature DB >> 30715202

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

A Vogel, A Cervantes, I Chau, B Daniele, J M Llovet, T Meyer, J-C Nault, U Neumann, J Ricke, B Sangro, P Schirmacher, C Verslype, C J Zech, D Arnold, E Martinelli.   

Abstract

Entities:  

Year:  2019        PMID： 30715202     DOI： 10.1093/annonc/mdy510

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  48 in total

1.  Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study.

Authors:  Sabrina Welland; Catherine Leyh; Fabian Finkelmeier; André Jefremow; Kateryna Shmanko; Maria A Gonzalez-Carmona; Arne Kandulski; Petia Jeliazkova; Jan Best; Thorben W Fründt; Angela Djanani; Maria Pangerl; Andreas Maieron; Richard Greil; Christina Fricke; Disorn Sookthai; Rainer Günther; Andreas Schmiderer; Henning Wege; Marino Venerito; Ursula Ehmer; Martina Müller; Christian P Strassburg; Arndt Weinmann; Jürgen Siebler; Oliver Waidmann; Christian M Lange; Anna Saborowski; Arndt Vogel
Journal:  Liver Cancer       Date:  2022-01-14       Impact factor: 12.430

Review 2.  Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Mirella Fraquelli; Tin Nadarevic; Agostino Colli; Cristina Manzotti; Vanja Giljaca; Damir Miletic; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2022-09-02

3.  A risk score model based on TGF-β pathway-related genes predicts survival, tumor microenvironment and immunotherapy for liver hepatocellular carcinoma.

Authors:  Jingsheng Liao; Qi Liu; Jingtang Chen; Zhibin Lu; Huiting Mo; Jun Jia
Journal:  Proteome Sci       Date:  2022-06-22       Impact factor: 2.882

Review 4.  Quality of Life and Cost Considerations: Y-90 Radioembolization.

Authors:  Stephen J Williams; William S Rilling; Sarah B White
Journal:  Semin Intervent Radiol       Date:  2021-10-07       Impact factor: 1.780

5.  Alpha-fetoprotein response at different time-points is associated with efficacy of nivolumab monotherapy for unresectable hepatocellular carcinoma.

Authors:  Wei Teng; Chen-Chun Lin; Ming-Mo Ho; Kar-Wai Lui; Sheng-Fu Wang; Chao-Wei Hsu; Shi-Ming Lin
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

6.  Follow-up of percutaneous microwave (MW) ablation of hepatic lesion: predictive value of CT at 24-h compared with CT at 1 month.

Authors:  Enrico Maria Fumarola; Anna Maria Ierardi; Pierpaolo Biondetti; Anna Paola Savoldi; Pasquale Grillo; Giovanna Gorga; Andrea Coppola; Gianpaolo Carrafiello
Journal:  Med Oncol       Date:  2020-04-07       Impact factor: 3.064

Review 7.  Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates.

Authors:  Dmitrii Shek; Scott A Read; Adnan Nagrial; Matteo S Carlino; Bo Gao; Jacob George; Golo Ahlenstiel
Journal:  Oncologist       Date:  2021-04-21

8.  Circulating microRNA‑135a‑3p in serum extracellular vesicles as a potential biological marker of non‑alcoholic fatty liver disease.

Authors:  Hemin Jiang; Yu Qian; Ziyang Shen; Yuwei Liu; Yunqiang He; Rui Gao; Min Shen; Shu Chen; Qi Fu; Tao Yang
Journal:  Mol Med Rep       Date:  2021-05-06       Impact factor: 2.952

9.  International trends in hepatocellular carcinoma incidence, 1978-2012.

Authors:  Jessica L Petrick; Andrea A Florio; Ariana Znaor; David Ruggieri; Mathieu Laversanne; Christian S Alvarez; Jacques Ferlay; Patricia C Valery; Freddie Bray; Katherine A McGlynn
Journal:  Int J Cancer       Date:  2019-11-05       Impact factor: 7.316

10.  HDAC1/2 Inhibitor Romidepsin Suppresses DEN-Induced Hepatocellular Carcinogenesis in Mice.

Authors:  Hara Afaloniati; Katerina Angelopoulou; Alexander Giakoustidis; Alexandros Hardas; Athanasios Pseftogas; Kali Makedou; Athanasios Gargavanis; Thomas Goulopoulos; Stavros Iliadis; Vasileios Papadopoulos; Apostolos Papalois; George Mosialos; Theofilos Poutahidis; Dimitrios Giakoustidis
Journal:  Onco Targets Ther       Date:  2020-06-15       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.